Please assess the completion status of the following clinical trial:

Trial Title: Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for Mothers:~* HIV infected~* Pregnant with a viable fetus~* Between 28 and 38 weeks of pregnancy~* CD4 count greater than 250 cells/mm3 within 30 days prior to study entry~* Able to receive oral ART during labor~* Willing to use acceptable forms of contraception while on study treatment~* Able to provide written informed consent~Exclusion Criteria for Mothers:~* Known allergy or hypersensitivity to ddI, LPV, NVP, ritonavir (RTV), or ZDV~* Any ART other than ZDV during a previous pregnancy or the current pregnancy~* Certain medications~* Planning to receive additional ART during the first 8 weeks postpartum~* Planning to breastfeed~* Unlikely to comply with postpartum study requirements, in the opinion of the investigator~* Certain abnormal laboratory values within 30 days prior to study entry

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: LPV/r x 7d (Type: EXPERIMENTAL): NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and BID for 7 days postpartum, ddI 250 mg orally daily (if body weight \<60 kg) or 400 mg orally twice daily (if body weight \>= 60 kg) at the onset of labor, during labor, and for 7 days postpartum, LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 7 days postpartum.
- Arm B: no LPV/r (Type: EXPERIMENTAL): NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight \<60 kg) or 400 mg orally daily (if body weight \>= 60 kg) at the onset of labor, during labor, and for 30 days postpartum.
- Arm C: LPV/r x 30d (Type: EXPERIMENTAL): NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight \<60 kg) or 400 mg orally daily (if body weight \>= 60 kg) at the onset of labor, during labor, and for 30 days postpartum,LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 30 days postpartum.

Based on this trial design, predict the completion outcome and termination type (if applicable).